Earnings Data
Report Date
Jul 23, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
5.97Last Year’s EPS
5.55Same Quarter Last Year
Moderate Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated a majority of positive operating and financial developments—revenue growth (+4.3%), strong EPS expansion (~11%), robust cash flow (+22%), sizable share repurchases, and a $200M incremental benefit from Medicaid supplemental programs—while acknowledging several meaningful headwinds including a sharp decline in respiratory-driven volumes, a January winter storm (combined ~$180M EBITDA drag), exchange-related revenue pressure (~$150M Q1; $600M–$900M full-year range), margin compression (‑50 bps) and rising denials. Management characterized the respiratory and weather impacts as temporal, reiterated full-year guidance and reaffirmed resiliency and AI-driven cost-efficiency plans. On balance, the company reported core growth and reinforced confidence in its balance sheet and guidance but faces significant payer and volume dynamics to monitor.Company Guidance
Revenue Growth
Total revenue increased 4.3% year-over-year in Q1 2026.
Adjusted EBITDA and EPS Improvement
Adjusted EBITDA increased almost 2% year-over-year in Q1; diluted earnings per share, as adjusted, increased approximately 11% versus prior-year period.
Strong Operating Cash Flow and Capital Actions
Cash flow from operations was $2.0 billion in the quarter, a 22% increase year-over-year; capital expenditures totaled $1.1 billion; $1.57 billion of shares repurchased and $183 million paid in dividends.
Medicaid Supplemental Payment Benefit
Net benefit from Medicaid supplemental programs increased approximately $200 million to adjusted EBITDA in Q1 (driven by Georgia grandfathered approval, reinstatement of Texas Atlas program and Tennessee benefit).
Network Expansion and Capital Investment
Sites of care expanded by more than 4% vs prior-year quarter, hospital beds increased almost 1% via capital spending, and emergency room capacity increased 4%.
Improved Quality and Operational Metrics
Company reported improved quality measures, increased patient satisfaction and reductions in average length of stay; case mix modestly up with notable growth in cardiac procedures and trauma (trauma +2.5%); patient logistics center admissions +2.4%.
Progress on Digital Transformation and AI
Rollout of AI and digital initiatives expanded (ambient documentation, nurse handoff programs, case management tools) with early productivity and safety improvements cited.
Balance Sheet and Leverage
Debt-to-adjusted EBITDA leverage remains in the lower half of the stated target range and management described the balance sheet as strong and well positioned.
Guidance Reaffirmation and Resiliency Plan
Management reaffirmed full-year 2026 guidance ranges and reiterated expected resiliency savings (approximately $400 million program) and confidence that temporal Q1 headwinds will not change full-year assumptions.
CH:2BH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FAQ
When does Hca Healthcare (CH:2BH) report earnings?
Hca Healthcare (CH:2BH) is schdueled to report earning on Jul 23, 2026, Before Open (Confirmed).
What is Hca Healthcare (CH:2BH) earnings time?
Hca Healthcare (CH:2BH) earnings time is at Jul 23, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Hca Healthcare stock?
The P/E ratio of HCA Healthcare is N/A.
What is CH:2BH EPS forecast?
CH:2BH EPS forecast for the fiscal quarter 2026 (Q2) is 5.97.
